Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Insights From a Single Institution Registry

Dual-antiplatelet therapy is recommended for all patients with acute coronary syndromes (ACS), regardless of performance of revascularization. Ticagrelor (T) was shown to be superior to clopidogrel (C) in a large, randomized clinical trial, but data from real-world practice are lacking. We identifie...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of invasive cardiology 2019-08, Vol.31 (8), p.235-238
Main Authors: Brener, Sorin J, Alapati, Venkatesh, Benson, Max M, Chan, Doris, Cunn, Gregory, Khan, Saadat, Kutkut, Issa, Narayanan, C Arun, O'Laughlin, John P, Sacchi, Terrence J
Format: Article
Language:English
Subjects:
Acute Coronary Syndrome - diagnosis
Acute Coronary Syndrome - mortality
Acute Coronary Syndrome - therapy
Aged
Cause of Death - trends
Clopidogrel - administration & dosage
Coronary Angiography
Dose-Response Relationship, Drug
Female
Follow-Up Studies
Humans
Incidence
Male
Middle Aged
Percutaneous Coronary Intervention
Platelet Aggregation Inhibitors - administration & dosage
Postoperative Complications - epidemiology
Postoperative Complications - prevention & control
Purinergic P2Y Receptor Antagonists - administration & dosage
Registries
Retrospective Studies
Survival Rate - trends
Ticagrelor - administration & dosage
Treatment Outcome
United States - epidemiology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dual-antiplatelet therapy is recommended for all patients with acute coronary syndromes (ACS), regardless of performance of revascularization. Ticagrelor (T) was shown to be superior to clopidogrel (C) in a large, randomized clinical trial, but data from real-world practice are lacking. We identified ACS patients from our institutional registry who underwent percutaneous coronary intervention and received one of the two drugs at hospital discharge based on physician preference. Among 1439 patients, there were 774 patients (53.8%) in the C group and 665 patients (46.2%) in the T group. T and C patients were similar except for a higher incidence of ST-elevation myocardial infarction (MI) and lower frequency of prior MI in the T group (P
ISSN:1557-2501